Easy ph1 first patient. Second reason dacoge goes off patent at end of 2013. Hopefully sgi-110 can also go after this cancer. This is huge news and it validates that these drugs can act as priming agents to other therapies.
One way to extend expiring patents of old drugs in pill form is to combine two or more into a single pill. The combination can be patented. While this is not the combination in a single pill is it possible that the treatment (dacogen and vaccine) can be patented?
My sense is that the CR was more due to the vaccine, the effect of which was enhanced by the use of Dacogen. As you say, the key is whether this can be replicated with other patients/cancers/vaccines and whether SG-110 will enhance this effect and provide a patented replacement for Dacogen after 2013.